Division of BRF
Center for Molecular Imaging & Therapy
About Us
Theranostic Research Center
The Center for Molecular Imaging and Therapy (CMIT) is a comprehensive molecular imaging & therapy research center housing clinical and pre-clinical PET/CT imaging, research laboratories, and radiopharmaceutical manufacturing based in Shreveport, Louisiana, USA.
0+
0+
Skilled Professionals
Serving the industry
0
0
Years Experience
Pioneering molecular imaging and therapy
0
0
States
Coast to coast theranostic research and care
0k+
0k+
Scans
Over 50,000 clinical & research scans to date
Our Reach
15 States & Counting
Coast to coast theranostic research and care
Services
What we do
Full-service molecular imaging research center housing clinical and pre-clinical PET/CT imaging, research laboratories, with radiopharmaceutical and targeted radiotherapy manufacturing based in Shreveport, Louisiana, USA.
01
Pre-Clinical
CMIT advances early-stage drug discovery with comprehensive research capabilities. Our facility includes a vivarium, PET and SPECT imaging, optical imaging, and nine specialized labs for chemistry, tissue culture, and biodistribution. We help partners move from concept to clinical application with precision and efficiency.
Manufacturing
CMIT produces a full range of diagnostic and therapeutic radiopharmaceuticals on site using compliant labs, a dedicated cyclotron, and an in-house nuclear pharmacy. We offer contract production, quality control testing, and national distribution to support research and clinical needs with speed and reliability.
02
03
Clinical Imaging & Therapy
CMIT delivers high-quality imaging through advanced PET and CT systems designed for both clinical care and research. Our imaging services support everything from diagnosis and therapy planning to data collection for trials, providing accurate and consistent results that drive better decisions.
Team
CMIT Leadership
Our strength lies in the dedicated team of scientists, clinicians, and specialists pushing the field forward.
Staff
CMIT Staff
Administration
FAQs
What is CMIT?
The Center for Molecular Imaging and Therapy is an independent research organization with the mission to advance and perform pre-clinical and clinical imaging research, and to manufacture and distribute radiopharmaceuticals.
What is molecular imaging?
Molecular imaging is a group of procedures that uses molecular probes to provide functional information about the patient or subject being imaged. This is complimentary to imaging techniques such as MRI or CT which provide anatomic information by measuring density or water content. Molecular imaging is a critical component of healthcare for many diseases and provides very exciting research opportunities.
What does CMIT specialize in?
CMIT has expertise in all areas of molecular imaging but focuses on the positron emission tomography (PET) modality. CMIT has expertise in the development, optimization and manufacturing of radiopharmaceuticals, the use of radiopharmaceuticals in the clinical and research environment, and the assessment of the value and results of the use of radiopharmaceuticals in both the clinical and research environments.
What is a radiopharmaceutical?
A radiopharmaceutical is a drug that contains a small amount of radioactivity and is used for diagnostic or therapeutic purposes. CMIT is engaged in radiopharmaceutical science research. Specifically, the team has the experience and expertise to optimize radiochemistry synthesis, develop novel diagnostic and therapeutic agents, and perform large scale production of molecular imaging probes. Through CMIT’s manufacturing and distribution laboratories, CMIT provides radiopharmaceuticals for clinical and research applications.
What is PET Imaging?
PET imaging uses specific radiopharmaceuticals to produce images which contain information helpful for clinical and research applications. The information explored by a given PET imaging procedure depends upon the specific radiopharmaceutical used. CMIT offers procedures for a variety of oncology, neurology and cardiology indications using multiple in-house available radiopharmaceuticals. CMIT is also engaged in several clinical trials to understand diseases such as Alzheimer’s disease and prostate cancer.
What research is CMIT performing?
CMIT is focused on developing novel radiopharmaceuticals and investigating new applications of these radiopharmaceuticals for molecular imaging and therapy. CMIT has specialized facilities that includes radiochemistry research laboratories, biology laboratories, translational research facilities, cyclotron facilities, and clinical imaging facilities.
